CA1217717A - Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction - Google Patents

Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction

Info

Publication number
CA1217717A
CA1217717A CA000438588A CA438588A CA1217717A CA 1217717 A CA1217717 A CA 1217717A CA 000438588 A CA000438588 A CA 000438588A CA 438588 A CA438588 A CA 438588A CA 1217717 A CA1217717 A CA 1217717A
Authority
CA
Canada
Prior art keywords
hyaluronidase
treatment
urokinase
useful
infarction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000438588A
Other languages
English (en)
French (fr)
Inventor
Francesco Borrelli
Francesco Antonetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SpA
Original Assignee
Istituto Farmacologico Serono SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Farmacologico Serono SpA filed Critical Istituto Farmacologico Serono SpA
Application granted granted Critical
Publication of CA1217717A publication Critical patent/CA1217717A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
CA000438588A 1982-10-08 1983-10-07 Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction Expired CA1217717A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT49241/82A IT1189379B (it) 1982-10-08 1982-10-08 Composizione farmaceutica contenente un agente fibrinolitico ed un fattore di diffusione,utile per il trattamento dell'infarto miocardico
IT49241/1982 1982-10-08

Publications (1)

Publication Number Publication Date
CA1217717A true CA1217717A (en) 1987-02-10

Family

ID=11270058

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000438588A Expired CA1217717A (en) 1982-10-08 1983-10-07 Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction

Country Status (12)

Country Link
US (1) US4568543A (enExample)
EP (1) EP0106812B1 (enExample)
JP (1) JPS5989630A (enExample)
AT (1) ATE44467T1 (enExample)
AU (1) AU559192B2 (enExample)
CA (1) CA1217717A (enExample)
DE (2) DE106812T1 (enExample)
DK (1) DK161564C (enExample)
ES (1) ES8704736A1 (enExample)
IL (1) IL69938A (enExample)
IT (1) IT1189379B (enExample)
ZA (1) ZA837484B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5275812A (en) * 1985-06-07 1994-01-04 The General Hospital Corporation Method of treatment for myocardial infarction
US5279824A (en) * 1988-04-14 1994-01-18 Merck Patent Gmbh Pharmaceutical formulation containing heparin and endo-beta-glucuronidase, useful for the treatment of thrombosis
HK1003981A1 (en) * 1989-01-27 1998-11-13 Immunolytics, Inc. Composition and method for treating benign prostatic hypertrophy
AU6470590A (en) 1989-10-23 1991-04-26 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5939412A (en) * 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
JPH10511356A (ja) * 1994-12-22 1998-11-04 スミスクライン・ビーチャム・コーポレイション フィブリノゲン受容体拮抗物質
AU2003220115A1 (en) * 2002-05-20 2003-12-12 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1179787A (en) * 1967-03-22 1970-01-28 Biorex Laboratories Ltd Stabilised and Potentiated Therapeutic Enzyme Compositions
US3708575A (en) * 1970-05-13 1973-01-02 Biorex Laboratories Ltd Method for the treatment of atherosclerosis employing glucuronoglycos-aminoglycan-hyaluronate-lyase
US4271150A (en) * 1979-03-07 1981-06-02 Zeria-Shinyaku Kogyo Kabushiki Kaisha Urokinase preparation for oral administration

Also Published As

Publication number Publication date
IL69938A (en) 1987-09-16
US4568543A (en) 1986-02-04
DK464483A (da) 1984-04-09
AU1988383A (en) 1984-04-12
IL69938A0 (en) 1984-01-31
IT1189379B (it) 1988-02-04
IT8249241A0 (it) 1982-10-08
EP0106812A3 (en) 1985-09-11
AU559192B2 (en) 1987-02-26
DK161564C (da) 1992-01-06
DK464483D0 (da) 1983-10-07
ATE44467T1 (de) 1989-07-15
EP0106812A2 (en) 1984-04-25
JPS5989630A (ja) 1984-05-23
ZA837484B (en) 1984-06-27
DK161564B (da) 1991-07-22
ES526300A0 (es) 1987-05-01
DE106812T1 (de) 1984-08-30
DE3380166D1 (en) 1989-08-17
ES8704736A1 (es) 1987-05-01
EP0106812B1 (en) 1989-07-12
IT8249241A1 (it) 1984-04-08
JPS6150927B2 (enExample) 1986-11-06

Similar Documents

Publication Publication Date Title
US5032608A (en) Method and substrate composition for treating atherosclerosis
US5419901A (en) Use of arginase to control nitric oxide formation
Bodemar et al. Treatment of anaemia in inflammatory bowel disease with iron sucrose
Mannucci et al. Plasminogen activator response after DDAVP: a clinico-pharmacological study
CA1217717A (en) Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction
JP2000191539A (ja) ジンセノサイドＲｂ１からなる脳細胞又は神経細胞保護剤
Nowak et al. Hirudin in disseminated intravascular coagulation
Heiffer et al. Effect of lethal doses of bacterial endotoxin (E. coli) on sympathetic neurohormones in the rabbit
RU2730998C2 (ru) Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении
León et al. Arginine supplementation improves histone and acute‐phase protein synthesis during gram‐negative sepsis in the rat
CA1290692C (en) Substrate composition for treating atherosclerosis
US5491150A (en) Supplementary therpeutic agents for the treatment of immunodeficiency syndrome
US5248688A (en) Method and substrate composition for treating atherosclerosis
US3929995A (en) Method for treating diabetic ketoacidosis
EP0459377B1 (en) Use of E1 prostaglandin to cure male erectile inpotence
EP1190714A2 (en) Method for the treatment of thromboembolic disorders in patients with aspirin resistance
Negrier et al. Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma
US4343799A (en) Use of derivatives of 6α-methylprednisolone for the prevention or reduction of adriamycin-induced cardiotoxicity
Raymond et al. Possible mechanism for the antiarrhythmic effect of helium in anesthetized dogs
EP0700298B1 (en) Therapeutic use of hemoglobin in the treatment of blood vessel blockage
EP0219716A2 (en) Immunosuppressive agent
Vogel Introduction. Coronary thrombolysis: Second chance therapy—Maximizing the advantage
Rossi et al. Salicylate and increased vascular permeability due to hyaluronidase
JPH01110632A (ja) スーパーオキシドジスムターゼを使用した外科手術の方法
deMagalhaes-Silverman et al. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.

Legal Events

Date Code Title Description
MKEX Expiry